2016 News Releases

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
04/21/16New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress
Podium Presentation to Highlight Efficacy, Cardiovascular Safety, Sleep Quality, and Quality of Life in Patients Receiving Low-Dose Fenfluramine for the Treatment of Dravet Syndrome EMERYVILLE, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that new data on ZX008 (low-dose fenfluramine) will be presented at the 14th International Child Neurology C... 
Printer Friendly Version
03/10/16Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results
Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST EMERYVILLE, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2015. Corporate Update Investigational New Drug (IND) Application for the Phase 3 program for ZX008 for the... 
Printer Friendly Version
03/04/16Zogenix to Release Fourth Quarter and Full-Year 2015 Financial Results and Host Conference Call and Webcast on March 10
EMERYVILLE, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2015 after the market close, and will host a corporate update conference call and webcast on Thursday, March 10th at 4:30 PM Eastern Time. Thursday, March 10th @ 4:30 PM Eastern Time... 
Printer Friendly Version
02/03/16Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
EMERYVILLE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5th Annual Global Healthcare Conference in New York, NY, on February 10, 2016. LEERINK Partners 5th Annual Global... 
Printer Friendly Version
01/19/16Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development program for the Company’s investigational product, ZX008, as a treatment of seizures associated with Dravet syndrome, a rare and catastrophic form of childhood epilepsy. “The FDA grantin... 
Printer Friendly Version
01/11/16Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the first Phase 3 clinical trial for the Company’s lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome.  “We are extremely pleased to have advanced the ZX008 program to the start of the Phase 3 trial. It is an important step towa... 
Printer Friendly Version